Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Bevacizumab in Relapsed SCLC (SUKSES-B2)
NCT04939662Phase 2Completed
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in small cell lung cancer (SCLC). Primary endpoint: Objective Response Rate. Started Jun 2021; status: completed.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04939662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939662.